American College of Radiology Imaging Network

对多种遗传和环境途径的理解日益加深，这些途径有助于 癌症的发展导致了个性化癌症治疗方法的概念，并 预防。这需要技术来表征患者和肿瘤因素，这些因素将驱动特定的 有针对性的干预措施，并衡量其有效性。生物医学成像现在提供了一个机会 以前所未有的方式描述肿瘤解剖学、生理学和分子生物学。挑战在于 利用这项技术来开发支持开发的定量诊断方法 以及应用有针对性的治疗和预防性干预措施。自成立以来，ACRIN一直 开发和实施多中心临床试验，以确定成像在 癌症的检测、表征和监测。与布朗的生物统计中心合作 ACRIN已经组建了一个由数百名临床影像专家组成的独特组织，其他 国内外一百多家机构的临床医生和非医生研究人员 与致力于癌症成像研究的更广泛的癌症研究社区合作。 在下一个赠款周期中，ACRIN提出了与个性化主题相关的3个主要科学目标 癌症护理：1.有针对性地监测高危人群；2.确定癌症的特征，以便推动 靶向治疗；以及3.基于成像的预测和预后生物标记物的开发 有针对性的治疗。通过其在成像领域的持续领先地位，ACRIN将发挥关键作用 在癌症检测和治疗的进步中的作用。 ACRIN将致力于发现成像方法，以改善癌症护理。这包括确定最优的 方法早期发现肿瘤，为治疗提供最佳时机，制定治疗技术 了解癌症的特征及其对治疗的反应，以便选择最合适的治疗方法。

A growing understanding of the multiple genetic and environmental pathways that contribute to the development of cancer is leading to the concept of a personalized approach to cancer therapy and prevention. This requires techniques to characterize patient and tumor factors that will drive specific targeted interventions and measure their effectiveness. Biomedical imaging now offers the opportunity to characterize tumor anatomy, physiology, and molecular biology in unprecedented ways. The challenge is to harness this technology to develop quantitative approaches to diagnosis that will support the development and application of targeted treatments and preventive interventions. Since its inception, ACRIN has developed and implemented multicenter clinical trials to establish the effectiveness of imaging in the detection, characterization and monitoring of cancer. Working with its biostatistics center at Brown University, ACRIN has assembled a unique organization of hundreds of clinical imaging specialists, other clinicians, and non-physician researchers at more than a hundred institutions nationally and internationally working collaboratively with the broader cancer research community dedicated to cancer imaging research. Over the next grant cycle, ACRIN proposes 3 major scientific objective related to the theme of personalized cancer care: 1. targeted surveillance of at-risk populations; 2.characterization of cancer in order to drive targeted therapy; and 3. development of imaging-based predictive and prognostic biomarkers of response to targeted treatment. Through its continued leadership in the imaging community, ACRIN will play a pivotal role in the advancement of cancer detection and therapy. ACRIN will work to discover ways for imaging to improve cancer care. This includes determining the optimal methods to detect cancer early in order to provide the best opportunity for cure, and establishing techniques to characterize cancer and its response to treatment in order to choose the most appropriate therapy.